Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children

This phase II study is intended to determine the immunogenicity and safety of single dose and two doses of OSP:rTTHc cholera conjugate vaccine (CCV) with or without alum adjuvant. The study will guide the future dosing schedule and formulation of CCV (with or without Aluminum phosphate adjuvant) expected to be needed in adults and children in cholera-endemic region.

NCT Number	NCT07509047
Lead Sponsor	International Vaccine Institute Collaborators: EuBiologics Co.,Ltd, Massachusetts General Hospital
Conditions	Cholera Vaccination
Enrollment	390 participants
Start Date	2026-01-13
Primary Completion	2027-03 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-03